Numerous drugs aimed at these mutations have demonstrated encouraging outcomes in preclinical tumor models and clinical advancements include FDA-approved EZH2 inhibitors for cancers with SMARCB1 mutations and more targets are now identified through genome-wide screens for clinical trials (Malone and Roberts 2024). The gene discussed is EZH2; the disease is neoplasm.